论文部分内容阅读
尽管阿斯匹林疗效较小,但仍是预防卒中再发的最广泛药物。服用阿斯匹林期间仍发生卒中,其原因不详。作者分析了一系列服用阿斯匹林过程中再发脑卒中的病例。 患者系1988年5月到1992年12月Tel Aviv医疗中心的2231例缺血性率中(Ischemic Stroke IS)住院病例中的129例服用阿斯匹林期间再发缺血性脑卒中(ASAF)者,将ASAF病人的临床特征与三个对组进行比较,每个对照组均包括仅患一次IS后即服用阿斯匹林而未再发卒中的129例病人:一个对照组确定阿斯匹林的剂量与第一次IS的时间,以检测年龄,性别在ASAF中的作用;另一对照组确定年龄,性别与第一次IS时间,而不确定阿斯匹林的剂量,目的是评价卒中再发与阿斯匹
Despite its less potent efficacy, aspirin remains the most widely prescribed prophylaxis for recurrent stroke. Stroke is still taking place during aspirin use for an unknown reason. The authors analyzed a series of cases of recurrent stroke during aspirin use. Patient was recurrent ischemic stroke (ASAF) during aspirin use in a total of 129 in-hospital episodes of 2231 ischemic rates (Ischemic Stroke IS) at the Tel Aviv Medical Center between May 1988 and December 1992 , The clinical characteristics of ASAF patients were compared with three pairs of controls, each of which included 129 patients who took aspirin and did not have a second stroke after receiving only one IS: one control group identified Aspirin Lin dose and the first IS time to detect the role of age and gender in ASAF; another control group to determine the age, sex and first IS time, but not sure aspirin dose, the purpose is to evaluate Stroke recurrence and aspirin